Compounds for the photodecontamination of pathogens in blood
    1.
    发明授权
    Compounds for the photodecontamination of pathogens in blood 有权
    用于血液中病原体光致净化的化合物

    公开(公告)号:US06686480B2

    公开(公告)日:2004-02-03

    申请号:US10161589

    申请日:2002-06-03

    IPC分类号: C07D49300

    摘要: Psoralen compound compositions are synthesized which have substitutions on the 4, 4′, 5′, and 8 positions of the psoralen, which yet permit their binding to nucleic acid of pathogens. Reaction conditions that photoactivate these bound psoralens result in covalent crosslinking to nucleic acid, thereby inactivating the pathogen. Higher psoralen binding levels and lower mutagenicity results in safer, more efficient, and reliable inactivation of pathogens. In addition to the psoralen compositions, the invention contemplates inactivating methods using the new psoralens.

    摘要翻译: 合成补骨脂素化合物组合物,其在补骨脂素的4,4',5'和8位上具有取代,其仍然允许它们与病原体的核酸结合。 激活这些结合的补骨脂素的反应条件导致与核酸的共价交联,从而使病原体灭活。 更高的补骨脂素结合水平和较低的致突变性导致更安全,更有效和可靠的病原体失活。 除了补骨脂素组合物之外,本发明考虑使用新的补骨脂素的灭活方法。

    Method for photodecontamination of pathogens in blood using 5'-primary aminopsoralens
    2.
    发明授权
    Method for photodecontamination of pathogens in blood using 5'-primary aminopsoralens 失效
    使用5'-主要氨基补骨脂素对血液中病原体进行光致净化的方法

    公开(公告)号:US06503699B1

    公开(公告)日:2003-01-07

    申请号:US09375340

    申请日:1999-08-16

    IPC分类号: A01N102

    摘要: Psoralen compound compositions are synthesized which have substitutions on the 4, 4′, 5′, and 8 positions of the psoralen, which yet permit their binding to nucleic acid of pathogens. Reaction conditions that photoactivate these bound psoralens result in covalent crosslinking to nucleic acid, thereby inactivating the pathogen. Higher psoralen binding levels and lower mutagenicity results in safer, more efficient, and reliable inactivation of pathogens. In addition to the psoralen compositions, the invention contemplates inactivating methods using the new psoralens.

    摘要翻译: 合成补骨脂素化合物组合物,其在补骨脂素的4,4',5'和8位上具有取代,其仍然允许它们与病原体的核酸结合。 激活这些结合的补骨脂素的反应条件导致与核酸的共价交联,从而使病原体灭活。 更高的补骨脂素结合水平和较低的致突变性导致更安全,更有效和可靠的病原体失活。 除了补骨脂素组合物之外,本发明考虑使用新的补骨脂素的灭活方法。

    5′-primary aminoalkyl psoralen compositions with platelets
    5.
    发明授权
    5′-primary aminoalkyl psoralen compositions with platelets 失效
    具有血小板的5'-氨基烷基补骨脂素组合物

    公开(公告)号:US06218100B1

    公开(公告)日:2001-04-17

    申请号:US08900032

    申请日:1997-07-24

    IPC分类号: A01N102

    摘要: Psoralen compounds are synthesized which have substitutions on the 4, 4′, 5′, and 8 positions of the psoralen, which permit enhanced binding to nucleic acid of pathogens. Higher psoralen binding levels and lower mutagenicity are described, resulting in safer, more efficient, and reliable inactivation of pathogens in blood products. The invention contemplates inactivation methods using the new psoralens which do not compromise the function of blood products for transfusion. In particular, use of 5′-primary aminoalkyl psoralens to inactivate pathogens in platelets is disclosed.

    摘要翻译: 合成补骨脂素化合物,其在补骨脂素的4,4',5'和8位上具有取代,其允许增强与病原体核酸的结合。 描述了更高的补骨脂素结合水平和较低的致突变性,导致血液制品中病原体的更安全,更有效和可靠的失活。 本发明考虑使用新的补骨脂素的灭活方法,其不损害用于输血的血液制品的功能。 特别地,公开了使用5'-氨基烷基补骨脂素灭活血小板中的病原体。

    Psoralen compounds
    8.
    发明授权
    Psoralen compounds 失效
    补骨脂素化合物

    公开(公告)号:US06420570B1

    公开(公告)日:2002-07-16

    申请号:US09767611

    申请日:2001-01-22

    IPC分类号: C07D49300

    摘要: Psoralen compound compositions are synthesized which have substitutions on the 4, 4′, 5′, and 8 positions of the psoralen, which yet permit their binding to nucleic acid of pathogens. Reaction conditions that photoactivate these bound psoralens result in covalent crosslinking to nucleic acid, thereby inactivating the pathogen. Higher psoralen binding levels and lower mutagenicity results in safer, more efficient, and reliable inactivation of pathogens. In addition to the psoralen compositions, the invention contemplates inactivating methods using the new psoralens.

    摘要翻译: 合成补骨脂素化合物组合物,其在补骨脂素的4,4',5'和8位上具有取代,其仍然允许它们与病原体的核酸结合。 激活这些结合的补骨脂素的反应条件导致与核酸的共价交联,从而使病原体灭活。 更高的补骨脂素结合水平和较低的致突变性导致更安全,更有效和可靠的病原体失活。 除了补骨脂素组合物之外,本发明考虑使用新的补骨脂素的灭活方法。